BeiGene, Ltd. (ONC)vsSagimet Biosciences Inc. Series A Common Stock (SGMT)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
SGMT
Sagimet Biosciences Inc. Series A Common Stock
$4.62
-0.22%
HEALTHCARE · Cap: $157.06M
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
SGMT
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for SGMT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : SGMT
The strongest argument for SGMT centers on Price/Book, Debt/Equity.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : SGMT
The primary concerns for SGMT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while SGMT is a value play — different risk/reward profiles.
SGMT carries more volatility with a beta of 3.40 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 26/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Sagimet Biosciences Inc. Series A Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sagimet Biosciences Inc. (SGMT) is a cutting-edge biotechnology firm specializing in the development of innovative therapies for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through clinical trials, leveraging novel mechanisms aimed at significantly improving patient outcomes. With a seasoned leadership team and a comprehensive intellectual property portfolio, Sagimet is well-positioned to take advantage of the growing demand for effective treatments in the metabolic disease arena, presenting a promising opportunity for institutional investors looking to engage with the evolving biotech market.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?